The company said it may appeal.
The so-called '415 patent relates, in part, to certain ways Genentech (nyse: DNA - news - people ) makes antibodies by recombinant DNA technology.
Genentech said it uses this technology for many of its products and has confidential licensing agreements with a number of companies on the '415 patent. Genentech also receives royalties on products covered by one or more claims of the patent, also known as Cabilly.
The patent issue goes back to last February, when the Patent Office rejected all 36 claims of the Cabilly patent.
In May, Genentech requested continued reexamination and the Patent Office granted the request.
On Monday, however, the company said it received notification from the Patent Office that its claims of the Cabilly patent were rejected.
Genentech said it plans to file a response and, if necessary, appeal the rejection.
Shares of Genentech fell 71 cents to $77.25 in premarket trading. [标签:content1][标签:content2]
作者:admin@医学,生命科学 2011-04-25 05:14